The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Open accessAbstract
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway. Antibodies that block this pathway offer a promising new approach to treatment in advanced/metastatic non-small cell lung cancer (NSCLC). A systematic review of the literature was conducted to assess the association of PD-L1 with important patient and disease characteristics, the prognostic significance of PD-L1 expressing NSCLC tumors, and the value of PD-L1 as a predictive biomarker of response to anti-PD-1/PD-L1 treatments in advanced/metastatic NSCLC. A total of 35 eligible studies were selected for analysis. Methods used to determine PD-L1 in NSCLC tissue varied considerably; with different PD-L1 antibodies, antibody detection methods, and staining cut-offs. Immunohistochemistry was the most frequent type of PD-L1 assay. Overall, study evidence did not support an association between PD-L1 expression and gender, age, smoking history, tumor histology (adenocarcinoma vs. squamous cell carcinoma), performance status, pathologic tumor grade or EGFR/KRAS/ALK mutational status. In several studies, high PD-L1 expression was associated with shorter survival compared with low expression. Most evidence indicated that patients with high vs. low PD-L1 expression were more likely to experience treatment benefit with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab) in advanced NSCLC. Variability in the methods used to determine PD-L1 expression in NSCLC tissue suggests a need for standardized use of well-validated PD-L1 diagnostic assays. Although considerable research links PD-L1 expression in tumors to shorter survival in advanced/metastatic NSCLC, its use as a prognostic factor requires more study. As studies of anti-PD-1/PD-L1 agents continue, PD-L1 is likely to play an important role as a predictive biomarker for selecting patients deriving most benefit from anti-PD-1/PD-L1 monotherapy and directing patients with lower levels of tumor PD-L1 expression (with a high unmet medical need), to alternative treatments, such as combination immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
The Global Burden of Cancer 2013
Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., MacIntyre, M. F., Allen, C., Hansen, G., Woodbrook, R., Wolfe, C., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0735 · Cited by 2,707
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., Fazzalari, L., Zahaf, K., Lalvée, S., Washetine, K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv489 · Cited by 587
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 435
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Wu, P., Wu, D., Li, L., Chai, Y., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131403 · Cited by 352
Ratcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
Self-citationPD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Cooper, W. A., Tran, T., Vilain, R. E., Madore, J., Selinger, C. I., Kohonen-Corish, M., Yip, P., Yu, B., O’Toole, S. A., McCaughan, B. C., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.007 · Cited by 294
Zhang, P., Su, D.-M., Liang, M., & Fu, J. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.013 · Cited by 263
Engel, K. B., & Moore, H. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0702-rair.1 · Cited by 257
Ilie, M., Hofman, V., Dietel, M., Soria, J.-C., & Hofman, P. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1910-4 · Cited by 257
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
Wang, A., Wang, H. Y., Liu, Y., Zhao, M. C., Zhang, H. J., Lu, Z. Y., Fang, Y. C., Chen, X. F., & Liu, G. T. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2015.01.020 · Cited by 255
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3694 · Cited by 243
Self-citationPD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Schmidt, L. H., Kümmel, A., Görlich, D., Mohr, M., Bröckling, S., Mikesch, J. H., Grünewald, I., Marra, A., Schultheis, A. M., Wardelmann, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136023 · Cited by 231
Chen, Y.-B., Mu, C.-Y., & Huang, J.-A. (2012) · Tumori Journal · doi:10.1177/030089161209800612 · Cited by 218
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 164
Rizvi, N. A., Brahmer, J. R., Ou, S.-H. I., Segal, N. H., Khleif, S., Hwu, W.-J., Gutierrez, M., Schoffski, P., Hamid, O., Weiss, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8032 · Cited by 159
Paz-Ares, L. G., Horn, L., Borghaei, H., Spigel, D. R., Steins, M. B., Ready, N., Chow, L. Q. M., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba109 · Cited by 146
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
Kerr, K. M., & Hirsch, F. R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0522-sa · Cited by 142
Pan, Z., Ye, F., Wu, X., An, H., & Wu, J. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.02.13 · Cited by 139
Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., Huang, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1094598 · Cited by 138
Self-citationZhang, J., Gao, J., Li, Y., Nie, J., Dai, L., Hu, W., Chen, X., Han, J., Ma, X., Tian, G., et al. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12247 · Cited by 127
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Lizotte, P. H., Ivanova, E. V., Awad, M. M., Jones, R. E., Keogh, L., Liu, H., Dries, R., Almonte, C. G., Herter-Sprie, G. S., Santos, A. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89014 · Cited by 125
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Chen, A. C., Ready, N., & Rizvi, N. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8023 · Cited by 125
Mahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 124
Mao, Y., Li, W., Chen, K., Xie, Y., Liu, Q., Yao, M., Duan, W., Zhou, X., Liang, R., & Tao, M. (2014) · Oncotarget · doi:10.18632/oncotarget.3097 · Cited by 122
Lin, C., Chen, X., Li, M., Liu, J., Qi, X., Yang, W., Zhang, H., Cai, Z., Dai, Y., & Ouyang, X. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.002 · Cited by 121
Spira, A. I., Park, K., Mazières, J., Vansteenkiste, J., Rittmeyer, A., Ballinger, M. D., Waterkamp, D., Kowanetz, M., Mokatrin, A., & Fehrenbacher, L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8010 · Cited by 121
Standardization of Diagnostic Immunohistochemistry: Literature Review and Geisinger Experience
Lin, F., & Chen, Z. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0074-ra · Cited by 115
Sholl, L. M., Aisner, D. L., Allen, T. C., Beasley, M. B., Borczuk, A., Cagle, P. T., Capelozzi, V. L., Đačić, S., Hariri, L. P., Kerr, K. M., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0506-sa · Cited by 113
Gettinger, S. N., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Alaparthy, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8024 · Cited by 104
Spigel, D. R., Gettinger, S. N., Horn, L., Herbst, R. S., Gandhi, L., Gordon, M. S., Cruz, C., Conkling, P., Cassier, P. A., Antonia, S. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8008 · Cited by 91
Gulley, J. L., Spigel, D. R., Kelly, K. L., Chandler, J. C., Rajan, A., Hassan, R., Wong, D. J. L., Leach, J., Edenfield, W. J., Wang, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8034 · Cited by 91
Sorensen, S. F., Zhou, W., Dolled-Filhart, M. P., Georgsen, J. B., Wang, Z., Emancipator, K., Wu, D., Busch-Sørensen, M., Meldgaard, P., & Hager, H. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.003 · Cited by 88
Xu, F., Xu, L., Wang, Q., An, G., Feng, G., & Liu, F. (2015) · PubMed · Cited by 83
Horn, L., Spigel, D. R., Gettinger, S. N., Antonia, S. J., Gordon, M. S., Herbst, R. S., Sequist, L. V. D., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8029 · Cited by 82
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., McLeod, D., & Hirsh, V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8049 · Cited by 81
Segal, N. H., Ou, S. I., Balmanoukian, A. S., Fury, M. G., Massarelli, E., Brahmer, J. R., Weiss, J., Schöffski, P., Antonia, S. J., Massard, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3011 · Cited by 80
Brahmer, J. R., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8112 · Cited by 79
Spigel, D. R., Chaft, J. E., Gettinger, S. N., Chao, B. H., Dirix, L. Y., Schmid, P., Chow, L. Q. M., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8028 · Cited by 73
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
Zhou, Z., Zhan, P., & Song, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.03.02 · Cited by 72
Besse, B., Johnson, M., Janne, P. A., Garassino, M. C., Eberhardt, W., Besse, B., Johnson, M., Janne, P. A., Garassino, M. C., Eberhardt, W., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31938-4 · Cited by 72
Zhou, F., Jiang, T., Ma, W., Gao, G., Chen, X., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.005 · Cited by 67
Hellmann, M. D., Gettinger, S. N., Goldman, J. W., Brahmer, J. R., Borghaei, H., Chow, L. Q. M., Ready, N., Gerber, D. E., Juergens, R. A., Shepherd, F. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3001 · Cited by 67
Rizvi, N. A., Garon, E. B., Patnaik, A., Gandhi, L., Leighl, N. B., Balmanoukian, A. S., Goldman, J. W., Eder, J. P., Johnson, E. A., Blumenschein, G. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8007 · Cited by 63
Liu, S. V., Powderly, J. D., Camidge, D. R., Ready, N., Heist, R. S., Hodi, F. S., Giaccone, G., Liu, B., Wallin, J. J., Funke, R. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8030 · Cited by 61
Antonia, S. J., Goldberg, S. B., Balmanoukian, A. S., Sanborn, R. E., Steele, K. E., Narwal, R., Robbins, P. B., Gu, Y. L., Karakunnel, J. J., & Rizvi, N. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3014 · Cited by 47
Spigel, D. R., Reckamp, K. L., Rizvi, N. A., Poddubskaya, E. V., West, H., Eberhardt, W., Baas, P., Antonia, S. J., Płużański, A., Vokes, E. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8009 · Cited by 46
Borghaei, H., Brahmer, J. R., Horn, L., Ready, N., Steins, M. B., Felip, E., Paz-Ares, L. G., Arrieta, O. G., Barlési, F., Antonia, S. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9025 · Cited by 42
Rizvi, N. A., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Goldman, J. W., Juergens, R. A., Borghaei, H., Ready, N., Gerber, D. E., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.204 · Cited by 37
Vansteenkiste, J., Fehrenbacher, L., Spira, A. I., Mazières, J., Park, K., Smith, D. A., Artal, A., Lewanski, C. R., Braiteh, F., Yi, J., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(15)30072-1 · Cited by 36
Gettinger, S. N., Hellmann, M. D., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Goldman, J. W., Juergens, R. A., Borghaei, H., Ready, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8025 · Cited by 36
Zhang, X., Huang, B., Chen, L., Bao, C., Sun, C., Li, J., & Wang, L. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s91025 · Cited by 32
Higgs, B. W., Robbins, P. B., Blake-Haskins, J. A., Zhu, W., Morehouse, C., Brohawn, P. Z., Rebelatto, M. C., Yao, Y., Jin, X., Shi, L., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31937-2 · Cited by 32
Rebelatto, M. C., Mistry, A., Sabalos, C., Walker, J., Midha, A., Steele, K. E., Robbins, P. B., Li, X., Shi, L., Blake-Haskins, J. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8033 · Cited by 29
Self-citationThe need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos, K., Saif, M. W., Karapanagiotou, E. M., Oikonomopoulos, G., & de Marinis, F. (2011) · PubMed · Cited by 28
Gainor, J. F., Sequist, L. V. D., Shaw, A. T., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Fulton, L. E., Schultz, K. R., Hata, A. N., Engelman, J. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8012 · Cited by 26
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.209 · Cited by 23
Antonia, S. J., Gettinger, S. N., Goldman, J. W., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Brahmer, J. R., Shen, Y., Harbison, C. T., Chen, A. C., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.207 · Cited by 19
PD-L1 gene expression in Japanese lung cancer patients
Sasaki, H., Suzuki, A., Shitara, M., Hikosaka, Y., Okuda, K., Moriyama, S., Yano, M., & Fujii, Y. (2012) · Biomedical Reports · doi:10.3892/br.2012.10 · Cited by 14
Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab
Boyd, Z. S., Smith, D. M., Baker, B., Vennapusa, B., Koeppen, H., Kowanetz, M., Mariathasan, S., Bruey, J., Mackey, H. M., Fine, G. D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr15-b001 · Cited by 9
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N. B., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M. A., Horn, L., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct104 · Cited by 4
Schmid, P., Kowanetz, M., Koeppen, H., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31661-6 · Cited by 3
Zalcman, G., Rizvi, N. A., Léna, H., Wolf, J., Mazières, J., Antonia, S. J., Minenza, E., Planchard, D., Lestini, B. J., & Ramalingam, S. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv050.08 · Cited by 1
Cited by
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 256
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
de Jong, C., Herder, G. J. M., & Deneer, V. H. M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13683 · Cited by 8
Metadata
- Authors
- Brody, R., Zhang, Y., Ballas, M., Siddiqui, M. K., Gupta, P., Barker, C., Midha, A., & Walker, J.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 112
- Pages
- 200-215
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2743614427
- Cited by
- 317
- References
- 85
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.